Drug Development: A Guide for Aspiring Researchers

Evaluate disease relevance, druggability, selectivity, tissue accessibility, and genetic validation to prioritize targets with binding pockets for structure-based design and therapeutic impact.

Explore genomics and transcriptomics, proteomics and functional screens, and computational networks to identify disease targets and triangulate evidence for high-confidence drug targets.

Validate drug targets by proving that inhibiting or activating candidate proteins improves disease outcomes, using genetics and pharmacology across disease models and human data.

Form a therapeutic hypothesis by linking a validated target to a clear mechanism and disease link, selecting a feasible modality such as a small molecule, antibody, or RNA therapy.

Bridge biology and chemistry to transition from validated target to compound discovery, using molecular docking, virtual and experimental screens, and structure based drug design to identify and optimize drug leads.

Explore molecular recognition and binding affinity, detailing non-covalent interactions—hydrogen bonds, ionic, van der Waals, and hydrophobic contacts—that drive ligand binding to protein targets.

Explore molecular docking and modeling as core computational tools that predict how a ligand fits a protein binding site, estimate affinity, and rank poses with scoring functions.

Learn to set up a docking workflow with software classes: drawing tools, visualization, docking engines, libraries, and protein databases, using Mole view, Chimera, AutoDock Vina, Protein Data Bank, and Zinc.

Execute a full docking workflow with Molview and Chimera, preparing ligands and proteins, defining the binding site, running Autodock Vina, and analyzing poses and hydrogen bonds to interpret docking results.

Explore an optional advanced docking workflow using Chemdraw, Chem3D, and Yasara to build a ligand, perform energy minimization, run docking, and analyze binding energies and interactions with heparinase.

Explore chemical libraries and in silico virtual screening to prioritize commercially available compounds for docking, using structure-based and ligand-based drug design, pharmacophore models, molecular fingerprints, and machine learning.

Review section three on molecular recognition, binding affinity, and docking, highlighting hands-on use of free tools like Chimera and Autodock Vina for docking and virtual screening toward lead optimization.

Explore how pharmacokinetics and pharmacodynamics determine a drug’s journey and effect, covering absorption, distribution, metabolism, excretion, dose–response, and the therapeutic window.

Apply Lipinski's rule of five to assess molecular weight, logP, hydrogen bond donors and acceptors, and predict oral bioavailability, solubility, and cell membrane permeability to rank drug-like candidates.

Explore freely available adme prediction tools to estimate absorption, distribution, metabolism, excretion, and toxicity, using smiles strings to assess gut absorption, brain permeability, and cytochrome interactions.

Predict and prevent toxic liabilities early in drug discovery by using computational alerts to flag red-flag compounds with hepatotoxicity, cardiotoxicity, genotoxicity, cytotoxicity, and carcinogenicity.

Refine lead compounds into viable drug candidates by optimizing potency, selectivity, adme properties, and synthetic feasibility through SAR strategies such as bioisosteric replacement and scaffold hopping.

Design and optimize lead compounds, then conduct pre-clinical testing for toxicity, PK, PD, and stability. File an IND with the FDA and progress through four clinical phases, including post-marketing surveillance.

Explore the Belmont Report principles—respect for persons, informed consent, beneficence, and justice—and the three R's, guiding ethical drug development from preclinical animal research to postmarket safety.

Learn target discovery and validation, docking, modeling, and virtual screening to convert hit compounds into lead candidates. Navigate preclinical and clinical phases of drug development, IND, and ethical considerations.